NASDAQ •
Healthcare •
Biotechnology •
Quote as of 07/31/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization11.46 mln
Float7.50 mln
Earnings Date08/24/2026
Piotroski F-Score
2
/ 9
Weak
1-Year Forecast
5.26
Transformational upside
Relative Strength
11
/ 100
Significantly lagging
Debt / Equity
0.02
Debt-free
ROE
-98.96
Deeply negative
Dividend Yield
0.00%
No dividend
Business Description
BioVie Inc. is a US-based medical research company focused on developing treatments for brain disorders and serious liver conditions. Its two main drug candidates are BIV201, targeting fluid buildup caused by liver cirrhosis, and NE3107, which is being tested as a potential treatment for Alzheimer's disease, Parkinson's disease, and long COVID. Founded in 2013 and headquartered in Carson City, Nevada, the company was previously called NanoAntibiotics Inc. before rebranding in 2016.
